[Morbidity in transsexual patients with cross-gender hormone self-treatment].
BACKGROUND
The demand for sex reassignment in transsexual patients has increased as have the number of treatments. However, these patients run into troubles to be treated in Spanish public hospitals and the patients usually make use of self-therapy, without medical control, by suffering frequent side effects. In this paper, we have analysed these effects.


METHODS
Cross-sectional and descriptive study of the side effects of cross-gender hormone self-administration in 57 transsexuals, aged (median [SD]) 30(7) years.


RESULTS
Combined treatment with estrogen and cyproterone acetate in 31 male-to-female transsexuals was associated with hyperprolactinemia in 24/31 patients (77.4%) and elevation of liver enzymes in 4/31 (12.9%). Androgen treatment in 26 female-to-male transsexuals was associated with hyperprolactinemia in 10/26 patients (38.5%), elevation of liver enzymes in 5/26 (19.2%). The levels of total cholesterol, LDL-cholesterol and triglycerides were higher in female-to-male that in male-to-female transsexuals (197.3 [40.2] vs 160.6 [38.0] mg/dl, p = 0.033; 131.4 [29.4] vs 104.8 [26.4] mg/dl, p = 0.049; and 131.3 [62.7] vs 67.4 [25.6], p = 0.001, respectively). Total cholesterol/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol ratios were higher in female-to-male that in male-to-female transsexuals, too (4.94 [1.20] vs 3.32 [0.71], p = 0.006; and 3.20 [0.87] vs 2.04 [0.63], p = 0.003, respectively).


CONCLUSIONS
The alteration of the cardiovascular risk, the presence of hyperprolactinemia and the elevation of liver enzymes must be taken into account in transsexual patients with hormone treatment.
Becerra Fernández
A
A
Servicio de Endocrinología y Nutrición, Hospital Ramón y Cajal, Madrid. abecerra@hrc.insalud.es
de Luis Román
D A
DA
Piédrola Maroto
G
G
D000293:Adolescent; D000328:Adult; D002784:Cholesterol / Q000097:blood; D003430:Cross-Sectional Studies; D003534:Cyproterone / Q000627:therapeutic use*; D012734:Disorders of Sex Development; D004798:Enzymes / Q000378:metabolism; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000627:therapeutic use*; D006801:Humans; D006966:Hyperprolactinemia / Q000175:diagnosis; D008099:Liver / Q000201:enzymology; D008297:Male; D009017:Morbidity; D015995:Prevalence; D012189:Retrospective Studies; D012646:Self Administration; D012651:Self Medication / Q000009:adverse effects*; D013030:Spain / Q000453:epidemiology; D014189:Transsexualism / Q000188:drug therapy* / Q000453:epidemiology*
D004798:Enzymes; D004967:Estrogens; D012739:Gonadal Steroid Hormones; D002784:Cholesterol; D003534:Cyproterone